Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21338078 | 0.85 | PGR (0.43) | PGRKDM1AHRH3HRH1HRH2 | |
| SCHEMBL16698478 | 0.85 | PGR (0.43) | PGRKDM1AHRH3HRH1HRH2 | |
| SCHEMBL21727142 | 0.85 | PGR (0.43) | PGRKDM1AHRH3HRH1HRH2 | |
| SCHEMBL16391087 | 0.84 | PGR (0.42) | PGRKDM1AHRH3ALDH1A1HRH1 | |
| SCHEMBL16391127 | 0.82 | PGR (0.43) | PGRALDH1A1MAPK1TDP1CCR5 | |
| SCHEMBL16698132 | 0.82 | PGR (0.43) | PGRALDH1A1MAPK1TDP1CCR5 | |
| SCHEMBL14321119 | 0.74 | DRD2 (0.46) | KDM1AHRH1 | |
| SCHEMBL21338059 | 0.71 | PGR (0.41) | PGRHRH3ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL16391119 | 0.71 | PGR (0.41) | PGRHRH3ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL16698020 | 0.71 | KDM1A (0.44) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | PGR 611/4885KDM1A 2499/4885HRH3 258/4885 |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | PGR 611/4885KDM1A 2499/4885HRH3 258/4885 |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | BMX, BLK, BTK | PGR 611/4885KDM1A 2499/4885HRH3 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.